deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02186509

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Adult Anaplastic Astrocytoma Adult Anaplastic Ependymoma Adult Anaplastic Oligodendroglioma Adult Brain Stem Glioma Adult Diffuse Astrocytoma Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Adult Mixed Glioma Adult Oligodendroglioma Adult Pilocytic Astrocytoma Adult Pineal Gland Astrocytoma Adult Subependymal Giant Cell Astrocytoma Recurrent Adult Brain Tumor
Interventions Alisertib Hyperfractionated radiation therapy Quality-of-life assessment Stereotactic radiosurgery
Updated 15 times since 2017 Last updated: Apr 28, 2025 Started: Jan 30, 2015 Primary completion: Mar 31, 2017 Completion: Dec 31, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Adult Anaplastic Astrocytoma and Adult Anaplastic Ependymoma, this trial is completed. The trial is conducted by Millennium Pharmaceuticals, Inc. and has accumulated 15 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Nov 2017 · 9 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~May 2019 · 5 months · monthly snapshot~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Oct 2023 · 9 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Feb 2026 · 9 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

15 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE1

  2. May 2025 — Feb 2026 [monthly]

    Completed PHASE1

  3. Sep 2024 — May 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 10 earlier versions

  1. Jan 2023 — Oct 2023 [monthly]

    Completed PHASE1

  2. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1

  3. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE1

  4. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE1

  5. May 2019 — Oct 2019 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  6. Dec 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Jun 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

  8. Nov 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  9. Feb 2017 — Nov 2017 [monthly]

    Recruiting PHASE1

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Millennium Pharmaceuticals, Inc.
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations